Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment.

Clark, J I; Alpaugh, R K; von Mehren, M; Schultz, J; Gralow, J R; Cheever, M A; Ring, D B; Weiner, L M

Clark, J I; Alpaugh, R K; von Mehren, M; Schultz, J; Gralow, J R; Cheever, M A; Ring, D B; Weiner, L M.

Affiliation

Clark JI; Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.

Cancer Immunol Immunother ; 44(5): 265-72, 1997 Jul.

Article in En | MEDLINE | ID: mdl-9247561

Subject(s)

Adenocarcinoma/prevention & control; Antibodies, Anti-Idiotypic/biosynthesis; Antibodies, Bispecific/therapeutic use; Antibodies, Monoclonal/therapeutic use; Antibody Specificity; Receptor, ErbB-2/immunology; Vaccination; Adenocarcinoma/secondary; Cytotoxicity, Immunologic; Humans; Immunoglobulin Fab Fragments/immunology; Receptors, IgG/immunology

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Adenocarcinoma / Antibodies, Anti-Idiotypic / Vaccination / Antibodies, Bispecific / Receptor, ErbB-2 / Antibodies, Monoclonal / Antibody Specificity Type of study: Clinical_trials Limits: Humans Language: En Journal: Cancer Immunol Immunother Journal subject: ALERGIA E IMUNOLOGIA / NEOPLASIAS / TERAPEUTICA Year: 1997 Document type: Article Affiliation country: United States Country of publication: Germany

Search on Google

Add to My VHL

XML

PubMed Links